The results of the NKG2D-CAR-T preclinical trial were promising in solid tumors (including breast cancer) and the THINK clinical trial is currently recruiting to test the safety and activity of human NKG2D CAR referred to as NKR-2 43-45. This evidence concerns the gene KLRK1 and breast carcinoma.